Anew Labs reportedly completed its first external financing round on September 16, 2026, raising $290 million after spinning out of ByteDance. The round reportedly values the AI drug-discovery company at approximately $1.5 billion post-money, while ByteDance retains about 56% of the business.
That makes this more than a large funding headline. It is a test of whether a company born inside a consumer-internet giant can attract outside capital while pursuing drug programs that move on laboratory and clinical timescales—not app-release schedules.
The reported financing at a glance
The round is described as external, with participation from investors including HSG, IDG Capital, Hillhouse Investment, 5Y Capital, Gaorong Ventures, Primavera Venture Partners, Boyu Capital, SBP Group and the Shanghai Future Industries Fund. 5Y Capital’s precise role is described differently across reports, so it is best treated simply as a participating investor here.
| Item | Reported detail | Date or condition |
| Financing | First external round of $290 million | Completed September 16, 2026 |
| Post-money valuation | Approximately $1.5 billion | After the financing |
| ByteDance ownership | Approximately 56% | ByteDance reportedly remained the controlling shareholder |
| Corporate status | Anew Labs spun out of ByteDance | The separation was reported in June 2026 |
The structure answers an obvious question: this was not described as a purely internal ByteDance transfer. Outside investors participated, while ByteDance reportedly kept control. That combination gives Anew Labs an external price tag without cutting its connection to its former parent.
From ByteDance’s AI-for-Science team to Anew Labs
Anew Labs originated inside ByteDance’s AI-for-Science work, which was formed in 2021 under Liu Kai’s leadership. The company was reported to have completed its formal spin-off in June 2026, transferring algorithms, technology platforms and pipeline assets into the new business.
The separation does not mean the companies have become strangers. Anew Labs was reported to continue relying on ByteDance computing power after the spin-off. That arrangement leaves the company with a distinct corporate identity and outside investors while preserving access to infrastructure associated with its former parent.
This is the practical logic of the deal: separate the financing and governance needs of a long-cycle biotechnology business from the faster rhythm of a consumer-internet company, without necessarily severing every operational link.
What Anew Labs is building
Anew Labs is an AI-assisted drug-discovery company, not a conventional drugmaker with an approved medicine. Its consistently named tools cover different stages of computational research:
| Tool | Reported function |
| AnewFold | Protein-structure prediction |
| AnewDesign | Antibody design and optimization |
| AnewMind | Large language model reasoning assistant for drug-discovery decisions |
The company’s reported lead program involves orally bioavailable pan-IL-17 small-molecule inhibitors. The IL-17F/F project is reported to be in lead optimization, the stage where candidate molecules are refined before more advanced development work.
Anew was also described as working on an IL-4 receptor program and two undisclosed targets. Researchers associated with the company reportedly presented pan-IL-17 inhibitor work at the American Association of Immunologists’ annual meeting in Boston in April 2026.
The important boundary is easy to lose in the excitement around AI: computational tools and a lead-optimization program are not the same thing as a proven treatment. The financing does not establish clinical efficacy, a completed clinical trial or an approved medicine.
Why an external round matters while ByteDance remains in control
For Anew Labs, the reported valuation creates a reference point that did not exist when the work was an internal ByteDance project. Outside investors now have a stake in the company, and the financing can provide runway for drug programs whose development cycles are measured in years rather than product-update quarters.
An external valuation can also become useful currency in recruiting and retaining specialist talent. Drug discovery needs researchers who may spend a long time moving from computational designs to laboratory validation and, eventually, clinical development. A separately valued company can present that work through a structure tailored to biotechnology rather than through ByteDance’s core app business.
None of that guarantees a scientific result. It explains why the spin-off can be strategically useful even with ByteDance still holding approximately 56%: Anew Labs gains outside capital and a market-facing valuation, while ByteDance remains the controlling shareholder.
The next meaningful test is therefore not another eye-catching valuation figure. It is whether Anew Labs can turn its computational platforms and lead-optimization work into candidates that advance through the demanding stages of drug development. That is where the real distance between an AI financing story and a medicine begins.
